Among the medicines listed for NSCLC, Gefitinib has a defined role in EGFR-mutated locally advanced or metastatic NSCLC. Reversibly inhibits EGFR tyrosine kinase, reducing signaling in EGFR-dependent tumors. Its pharmacological class is EGFR TKI. EGFR pathway dependence is the key treatment concept, so molecular characterization of the tumor is closely tied to appropriate use. The database categorizes it as Targeted Therapy; EGFR Tyrosine Kinase Inhibitor and records regimen examples such as Gefitinib monotherapy. These combinations indicate how the agent fits into broader treatment programs rather than functioning as a universal therapy for every cancer in the tumor group. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Clinical interpretation should include the disease stage, histology, treatment history, and any molecular or receptor feature expressly named in the indication. The mechanism is useful for understanding why those selection criteria matter and why another drug from the same broad category may not be interchangeable. This summary has been written for an oncology medicines reference database and does not attempt to prescribe therapy for an individual patient. Because labels and guideline-supported uses can change, current product information should be checked when the entry is applied clinically.